A committee mber asked, "So, Dr. Schmidt, what’s your overall assessnt? Should this temporary pathway continue, or even expand? Should formal approval be expedited?"
Carl paused for a mont and gave a rigorous answer, "From a purely dical and patient benefit perspective, it should continue, and we should even consider appropriately expanding the range of diseases. From a regulatory and systemic risk perspective, we need to establish clearer exit chanisms and transformation pathways. If K Therapy ultimately fails to obtain formal approval for the market, how will we handle the subsequent treatnt and data ownership of these compassionate use patients? Additionally, we need to start a serious discussion about how to incorporate the cost of such breakthrough therapies into a sustainable healthcare system. This is not just a regulatory issue but also a health economic and social policy issue."
"So, your suggestion?"
"I suggest establishing an interdepartntal working group composed of experts in health, economics, law, and data protection, to specifically study sustainable access models for breakthrough therapies in Europe. We can’t always rely on temporary pathways; we need long-term chanisms."
This suggestion received the approval of most committee mbers. The eting decided that Carl would lead the preparation of this working group.
After the eting, Lillian Windsor stopped Carl.
"Carl, you seem to have changed?" Lillian smiled. "You used to prioritize rules and risks first, but now you’re actively pushing the advancent of K Therapy."
Carl smiled wryly, "Maybe I’ve been pushed by you all, as well as the faces behind the data. Last week, I visited a glioblastoma patient using compassionate use at Heidelberg University Hospital, a 30-year-old physics doctoral student. He told if he could live another year, he could complete his doctoral thesis, which might make a small contribution to quantum computing. At that mont, I wondered, are our rules ant to protect people like him, or could they inadvertently crush their hopes?"
"So, we need to design the rules smarter," Lillian said. "Not to obstruct, but to accelerate safely, and most importantly, our evaluation of every decision should be objective, without bias."
"Correcting bias is the hardest part; just because I’ve done it doesn’t an others can," Carl replied.
...
Nandu, Sanbo Research Institute.
In front of Yang Ping was the in-depth analysis report of the latest batch of single-cell sequencing data from Shen Guohua. The report showed that those lurking tumor cells, in addition to secreting disruptive factors, had their geno mutation rates abnormally rising and displayed features of microsatellite instability.
"Increased genomic instability." Yang Ping pointed to the mutation spectrum chart, "This ans they are accelerating trial and error, looking for new survival strategies, but it also ans they might be more sensitive to certain DNA damage repair inhibitors or immune checkpoint inhibitors. This is a weakness."
Song Zimo’s eyes lit up, "Can we try incorporating low-dose PARP inhibitors in the maintenance regin? Or, during the next vector infusion, combine it with a milder PD-1 inhibitor?"
"Theoretically, there’s synergy, but it requires extrely precise dose exploration to prevent additive toxicity." Yang Ping pondered, "Mr. Shen’s liver and bone marrow function are now like a tight string. Adding any new dication might disrupt the balance."
"But if we don’t add it, the tumor might find a complete escape thod amidst the accelerated mutation," Lu Xiaolu reminded.
"So, we need more precise data as a basis to grasp the art of this balance." Yang Ping murmured.
Many data are obtained through trial and error, and Yang Ping decided it was ti to spare so ti to the System Space Laboratory to collect data.
The automatic door of the laboratory opened gently, and Zhang Lin ca in carrying several bottles of milk tea, placing them on the table.
Zhang Lin said, "Professor, take a break, have so milk tea, everyone have so milk tea."
Yang Ping looked at the milk tea, "Do you need sothing from ?"
Zhang Lin had been looking for Professor Yang for a few days, but Professor Yang was always busy. He waited for a few days and finally got this free mont.
"Professor, I have a question to ask?" Zhang Lin was a bit embarrassed to interrupt Yang Ping.
"Go ahead." Yang Ping said.
Zhang Lin looked around mysteriously, as if about to say a secret.
"Should we avoid this?" Song Zimo gestured to everyone.
"No, no need!"
Zhang Lin chuckled.
"Professor! Professor, I found another secret; this secret can set up a new research topic, maybe even win a Nobel Prize."
Oh damn!
Teacher Zhang was no longer content with pursuing only surgical hooking skills; he was aiming for the Nobel Prize. Not only Song Zimo, but everyone perked up their ears, listening for his Nobel-Prize level topic.
Zhang Lin chuckled again, "Let make it clear first, this topic is my discovery; you can’t steal it, you must respect intellectual property rights."
Those around showed disapproving expressions, and Zhang Lin coughed, "Professor, my discovery is that we can adjust our breathing using different mudra gestures. Look, for instance, if I form a circular mudra gesture with my right thumb and forefinger pinching together, it results in chest breathing, then if I switch to a circular gesture with the thumb and ring finger pinching together, it imdiately switches to abdominal breathing. When you alternate the two gestures, your breathing thod switches too. It’s amazing, and I vaguely feel that cultivation might be real since qi cultivation in cultivation uses these gestures."
Song Zimo almost spat out the milk tea he’d been gulping down, is this for real?
He imdiately tried it, and others followed suit.
Oh damn! This is real; the gestures indeed control breathing. What is this principle? Everyone looked at Zhang Lin.
Zhang Lin raised his head, "If we can clearly understand the fundantal principles here, perhaps I can unlock cultivation. Wouldn’t you say this is Nobel Prize-level?"
```
User Comments
0 comments from readers